PR NEWSWIRE

immediapress comunicato stampa

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LACRIFILL® CANALICULAR GEL INCLUSION IN NEW DRY EYE WORKSHOP (DEWS) III MANAGEMENT AND THERAPY REPORT FROM THE TEAR FILM AND OCULAR SURFACE SOCIETY (TFOS) IN AMERICAN JOURNAL OF OPHTHALMOLOGY

BERWYN, Pa., Aug. 7, 2025 /PRNewswire/ -- Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announces that its LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, has been included in the new Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS).



SEGUICI SUI SOCIAL

threads whatsapp linkedin twitter youtube facebook instagram

ora in
Prima pagina
articoli
in Evidenza